Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

Steven A. Rosenberg, James C. Yang, Douglas J. Schwartzentruber, Patrick Hwu, Francesco M. Marincola, Suzanne L. Topalian, Nicholas P. Restifo, Mark E. Dudley, Susan L. Schwarz, Paul J. Spiess, John R. Wunderlich, Maria R. Parkhurst, Yutaka Kawakami, Claudia A. Seipp, Jan H. Einhorn, Donald E. White

Research output: Contribution to journalArticle

1627 Citations (Scopus)

Abstract

The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.

Original languageEnglish
Pages (from-to)321-327
Number of pages7
JournalNature Medicine
Volume4
Issue number3
DOIs
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Synthetic Vaccines
Subunit Vaccines
Melanoma
Gene encoding
Peptides
gp100 Melanoma Antigen
Neoplasm Genes
HLA-A2 Antigen
Antigens
Cancer Vaccines
Cloning
Interleukin-2
Assays
Therapeutics
Neoplasms
Molecules
Immunotherapy
Organism Cloning

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., ... White, D. E. (1998). Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine, 4(3), 321-327. https://doi.org/10.1038/nm0398-321

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. / Rosenberg, Steven A.; Yang, James C.; Schwartzentruber, Douglas J.; Hwu, Patrick; Marincola, Francesco M.; Topalian, Suzanne L.; Restifo, Nicholas P.; Dudley, Mark E.; Schwarz, Susan L.; Spiess, Paul J.; Wunderlich, John R.; Parkhurst, Maria R.; Kawakami, Yutaka; Seipp, Claudia A.; Einhorn, Jan H.; White, Donald E.

In: Nature Medicine, Vol. 4, No. 3, 1998, p. 321-327.

Research output: Contribution to journalArticle

Rosenberg, SA, Yang, JC, Schwartzentruber, DJ, Hwu, P, Marincola, FM, Topalian, SL, Restifo, NP, Dudley, ME, Schwarz, SL, Spiess, PJ, Wunderlich, JR, Parkhurst, MR, Kawakami, Y, Seipp, CA, Einhorn, JH & White, DE 1998, 'Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma', Nature Medicine, vol. 4, no. 3, pp. 321-327. https://doi.org/10.1038/nm0398-321
Rosenberg, Steven A. ; Yang, James C. ; Schwartzentruber, Douglas J. ; Hwu, Patrick ; Marincola, Francesco M. ; Topalian, Suzanne L. ; Restifo, Nicholas P. ; Dudley, Mark E. ; Schwarz, Susan L. ; Spiess, Paul J. ; Wunderlich, John R. ; Parkhurst, Maria R. ; Kawakami, Yutaka ; Seipp, Claudia A. ; Einhorn, Jan H. ; White, Donald E. / Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. In: Nature Medicine. 1998 ; Vol. 4, No. 3. pp. 321-327.
@article{911bf1c23c5d49148aa60a53ec79e256,
title = "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma",
abstract = "The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91{\%} of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42{\%}) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.",
author = "Rosenberg, {Steven A.} and Yang, {James C.} and Schwartzentruber, {Douglas J.} and Patrick Hwu and Marincola, {Francesco M.} and Topalian, {Suzanne L.} and Restifo, {Nicholas P.} and Dudley, {Mark E.} and Schwarz, {Susan L.} and Spiess, {Paul J.} and Wunderlich, {John R.} and Parkhurst, {Maria R.} and Yutaka Kawakami and Seipp, {Claudia A.} and Einhorn, {Jan H.} and White, {Donald E.}",
year = "1998",
doi = "10.1038/nm0398-321",
language = "English",
volume = "4",
pages = "321--327",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

AU - Rosenberg, Steven A.

AU - Yang, James C.

AU - Schwartzentruber, Douglas J.

AU - Hwu, Patrick

AU - Marincola, Francesco M.

AU - Topalian, Suzanne L.

AU - Restifo, Nicholas P.

AU - Dudley, Mark E.

AU - Schwarz, Susan L.

AU - Spiess, Paul J.

AU - Wunderlich, John R.

AU - Parkhurst, Maria R.

AU - Kawakami, Yutaka

AU - Seipp, Claudia A.

AU - Einhorn, Jan H.

AU - White, Donald E.

PY - 1998

Y1 - 1998

N2 - The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.

AB - The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.

UR - http://www.scopus.com/inward/record.url?scp=0031890206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031890206&partnerID=8YFLogxK

U2 - 10.1038/nm0398-321

DO - 10.1038/nm0398-321

M3 - Article

VL - 4

SP - 321

EP - 327

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 3

ER -